Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study
The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
Authors
- Yu-Hsuan Shih (ORCID: https://orcid.org/0000-0002-9823-3771)
- Cheng-Han Wu (ORCID: https://orcid.org/0000-0002-6994-1904)
- Hsin-Chen Lin
- Kuan-Yu Tseng (ORCID: https://orcid.org/0009-0004-4396-6056)
- Chiann-Yi Hsu
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- Taichung Veterans General Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17588359261420081
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00